1. Life-threatening thrombocytosis following GCSF treatment in a case of clozapine-induced agranulocytosis.
- Author
-
Dihingia S, Deka K, Bhuyan D, and Mondal SK
- Subjects
- Clozapine administration & dosage, Clozapine therapeutic use, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Granulocyte Colony-Stimulating Factor therapeutic use, Humans, India, Middle Aged, Thrombocytosis physiopathology, Agranulocytosis chemically induced, Clozapine adverse effects, Critical Illness, Granulocyte Colony-Stimulating Factor adverse effects, Thrombocytosis chemically induced
- Abstract
Clozapine was introduced in European market in 1972 as an effective treatment for schizophrenia without extrapyramidal side effects. Within a short while, the clozapine story virtually came to a halt following detection of life-threatening neutropenia and agranulocytosis. Judicial use of granulocyte colony stimulating factor (GCSF) can be life saving with infrequent side effects in these cases. Here we are presenting a case of clozapine induced agranulocytosis managed with GCSF but had transient but life-threatening thrombocytosis, a very uncommon complication of GCSF therapy. Expression of GCSF receptors on the surface of megakaryocytic lineage is thought to be the cause of this unusual phenomenon., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF